Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl- 1,3-dioxolane]platinum(II)

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 2, 1997, Pages 109-116

  Kim, Hun Taek ^a   Kim, Dae Kee ^a   Cho, Yong Baik ^a   Kim, Taek Soo ^a   Jung, Inho ^a   Kim, Key H ^a   Heo, Dae Seog ^c   Bang, Yung Jue ^c   Shin, Sang Goo ^b   Kim, Noe Kyeong ^c  

^a Sunkyong Industries   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

In vitro cytotoxicity; Pharmacokinetics; SKI 2053R

Indexed keywords

CISPLATIN; EPTAPLATIN; PLATINUM DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CELL SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM EXPOSURE; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA;

EID: 0031882342     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050716     Document Type: Article

References (28)

1. Alberts DS, Salmon SE, Chen H-SG, Moon TE, Young L, Surwit EA (1981) Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6: 253
2. Anderson N, Lokich JJ (1994) Cancer chemotherapy and infusional scheduling. Oncology 8: 99
3. Bergerat J-P, Barlogie B, Drewinko B (1979) Effects of cis-diamminedichloroplatinum(II) on human colon carcinoma cells in vitro. Cancer Res 39: 1334
4. Cahan MA, Walter KA, Colvin OM, Brem H (1994) Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33: 441
5. Carson RW, Sikic BI (1983) Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 99: 823
6. Cole WC, Wolf W (1980) Preparation and metabolism of a cisplatin/serum protein complex. Chem Biol Interact 30: 223
7. Curt GA, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE, Collins JM (1983) A phase 1 and pharmacokinetic study of diamminecyclobutanedicarboxylatoplatinum (NSC 242140). Cancer Res 43: 4470
8. Gale GR, Morris CR, Atkins LM, Smith AB (1973) Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents. Cancer Res 33: 813
9. Gormley PE, Bull JM, Leroy AF, Cysyk R (1979) Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 25: 351
10. Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197: 461
11. Kim D-K, Kim G, Gam J, Cho Y-B, Kim H-T, Tai J-H, Kim KH, Hong W-S, Park J-G (1994) Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1, 3-dioxolane]platinum(II) complexes. J Med Chem 37: 1471
12. Kim D-K, Kim H-T, Cho Y-B, Kim KH (1995) SK1-2053R. Drugs Future 20: 1128
13. Kim D-K, Kim H-T, Cho Y-B, Tae JH, Ahn JS, Kim T-S, Kim KH, Hong W-S (1995) Antitumor activity of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]-platinum(II), a new platinum analogue, as an anticancer agent. Cancer Chemother Pharmacol 35: 441
14. Kim D-K, Kim H-T, Tae JH, Cho Y-B, Kim T-S, Kim KH, Park J-G, Hong W-S (1995) Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R, 5R)-4, 5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) as determined by ex vivo pharmacodynamics. Cancer Chemother Pharmacol 37: 1
15. Kim NK, Bang Y-J, Heo DS, Kim TY, Lee JA, Park YI, Shin SG, Cho Y-B, Kim KH, Kim D-K (1995) A phase 1 clinical and pharmacokinetic study of SKI 2053R, a new platinum analog, in patients with malignancies. Proc Am Soc Clin Oncol 14: 479
16. Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine(1.1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46: 1972
17. Ludwig R, Alberts DS, Miller TP, Salmon SE (1984) Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay. Cancer Chemother Pharmacol 12: 135
18. Matsushima Y, Kanzawa F, Hoshi A, Shimizu E, Nomori H, Yasutsuna S, Saijo N (1985) Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 14: 104
19. Mauldin SK, Husain I, Sancar A, Chaney SG (1986) Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line. Cancer Res 46: 2876
20. Meyers FJ, Welborn J, Lewis JP, Flynn N (1989) Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 7: 173
21. Moran RE, Straus MJ (1981) Effects of pulse and continuous intravenous infusion of cis-diamminedichloroplatinum on L1210 leukemia in vivo. Cancer Res 41: 4993
22. Reece PA, Stafford I, Abbott RL, Anderson C, Denham J, Freeman S, Morris RG, Gill PG, Olweny CL (1989) Two-versus 24-hour infusion of cisplatin: pharmacokinetic considerations. J Clin Oncol 7: 270
23. Rosenberg B (1978) Platinum complex-DNA interactions and anticancer activity. Biochimie 60: 859
24. Salem P, Khalyl M, Jabboury K, Hashimi L (1984) cis-Diamminedichloroplatinum(II) by 5-day continuous infusion: a new dose schedule with minimal toxicity. Cancer 53: 837
25. Smit EF, Willemse PHB, Sleijfer DT, Uges DRA, Postmus PE, Meijer S, Terheggen PMAB, Mulder NH, De Vries EGE (1991) Continuous infusion carboplatin on a 21-day schedule: a phase 1 and pharmacokinetic study. J Clin Oncol 9: 100
26. Troger V, Fischel JL, Formento P, Gioanni J, Milano G (1992) Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. Eur J Cancer 28: 82
27. Vermorken JB, Vijgh WJF van der, Klein I, Gall HE, Pinedo HM (1982) Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum(II) and its therapeutic implications. Eur J Cancer Clin Oncol 18: 1069
28. Vijgh WJF van der (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 4: 242